Further insight into the mode of action of the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)

[1]  D. Grierson,et al.  Synthesis and chemistry of 5,6-dihydropyridinium salt adducts. Synthons for general electrophilic and nucleophilic substitution of the piperidine ring system , 2002 .

[2]  C. Mytilineou,et al.  Studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, Life sciences.

[3]  N. Castagnoli,et al.  Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1985, Life sciences.

[4]  J. Langston.  MPTP neurotoxicity: an overview and characterization of phases of toxicity. , 1985, Life sciences.

[5]  A. Brossi,et al.  Conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (mptp) and its 5-methyl analog into pyridinium salts† , 1984 .

[6]  W. M. Davis,et al.  Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse liver preparations. , 1984, Biochemical and biophysical research communications.

[7]  N. Castagnoli,et al.  Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. , 1984, Biochemical and biophysical research communications.

[8]  S. Snyder,et al.  Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. , 1984, European journal of pharmacology.

[9]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[10]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[11]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[12]  S. Finklestein,et al.  Effects of N-substituted phenyltetrahydropyridines on cerebral high-affinity synaptosomal uptake of dopamine and other monoamines in several mammalian species. , 1984, Life sciences.

[13]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[14]  B. Howard,et al.  Inhibition of dopamine uptake by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a cause of parkinsonism. , 1984, Biochemical and biophysical research communications.

[15]  D. Paty,et al.  Chronic parkinsonism secondary to intranasal administration of a product of meperidine-analogue synthesis. , 1984, The New England journal of medicine.

[16]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[17]  J. Raynaud,et al.  Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum , 1974, The Journal of pharmacy and pharmacology.

[18]  P. Portoghese,et al.  α-Cyanation of Tertiary Amines , 1980 .

[19]  V. P. Whittaker,et al.  The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. , 1962, Journal of anatomy.